#United States #Marlborough #Boston Scientific #Valencia Technologies #eCoin System

Boston Scientific's Strategic Acquisition of Valencia Technologies

Boston Scientific Corporation, a prominent name in medical technology, recently announced its definitive agreement to acquire Valencia Technologies Corporation, a privately held company specializing in innovative solutions for bladder dysfunction. This acquisition is particularly notable as it positions Boston Scientific to expand its offerings in the urology sector, specifically targeting overactive bladder (OAB), a condition afflicting nearly 30 million adults aged 40 and older in the United States alone.

The Need for Innovative Solutions

The symptoms of OAB can severely impact patients' quality of life, affecting their mental health, sleep quality, and social interactions. A staggering 19% of individuals suffering from OAB seek treatment beyond simple lifestyle changes. Boston Scientific recognizes this growing need and is poised to address it through the integration of Valencia Technologies' eCoin® System.

Details of the eCoin® System

The eCoin system, an FDA-approved tibial nerve stimulation device, represents a significant breakthrough in treating urge urinary incontinence (UUI), a common symptom of OAB. The device, which is approximately coin-sized, is surgically implanted under the skin near the ankle in a minimally invasive procedure. It offers a solution for patients who have previously responded well to percutaneous tibial nerve stimulation (PTNS) but require a more permanent option.

Upon implantation, the eCoin device automatically stimulates the tibial nerve, helping to enhance communication between the bladder and the brain. Results from a pivotal clinical trial demonstrated that 68% of participants experienced at least a 50% reduction in UUI episodes, indicating the device's effectiveness.

Expanding Urology Offerings

Meghan Scanlon, Senior Vice President and President of Urology at Boston Scientific, stated, "The addition of the eCoin system will allow us to venture into implantable tibial nerve stimulation, a rapidly growing area within our Urology business. This innovative technology complements our existing pelvic health product line, enabling us to offer a broader range of treatment options for patients."

Boston Scientific expects to finalize the acquisition in the first half of 2026, pending customary closing conditions. The financial impact of this transaction is anticipated to be immaterial on adjusted earnings per share for 2026 but may be more dilutive on a GAAP basis due to related charges and amortization expenses. While specific terms of the deal remain undisclosed, this acquisition is a strategic step for Boston Scientific as it seeks to enhance its market position in the urology space.

About Boston Scientific

For over 45 years, Boston Scientific has been at the forefront of medical technology, dedicated to improving patient health through innovative solutions. With a diverse portfolio of devices addressing complex cardiovascular, gastrointestinal, neurological, and urological conditions, the company aims to transform lives by advancing healthcare. Interested parties can learn more about their extensive range of products and services through their website or follow them on LinkedIn for updates.

Conclusion

The acquisition of Valencia Technologies marks a significant milestone for Boston Scientific in its goal to provide comprehensive healthcare solutions. With OAB affecting millions and current treatment rates being relatively low, the integration of the eCoin system could provide much-needed relief to countless individuals grappling with this disruptive condition. As Boston Scientific expands its offerings, the industry eagerly awaits the positive outcomes this acquisition could bring to patients across the country.